Hvsen Biotech announced that the operating revenue for 2024 is expected to be 1.2 billion yuan, a year-on-year increase of 17.71%. The net loss attributable to shareholders of the listed company is 20.1556 million yuan, compared to a net profit of 16.7808 million yuan in the same period last year, resulting in a loss from profit. The profit distribution plan approved by the board of directors is as follows: based on the total share capital of 166 million shares as of December 31, 2024, excluding 753,600 shares held in the repurchase special securities account, a cash dividend of 1.3 yuan will be distributed for every 10 shares to all shareholders, with 0 bonus shares, and a transfer of 0 shares from the capital reserve for every 10 shares to all shareholders